Enveda Biosciences, Inc.

Venture capital mega-rounds of $100m or more drove the overall increase in VC funding raised by biopharmaceutical companies in 2024, as Evaluate data recently revealed , and as the National Venture C

Venture capital mega-rounds of $100m or more have surged in 2024 and the trend has continued in December, with announcements on 19 December that Ottimo Pharma’s series A round brought in more than $14

Antibody-drug conjugate (ADC) developer Adcendo has been busy during the last year and a half since the company raised a €31m ($32.3m) extension of the €51m ($53.2m) series A it originally raised in 2

Investor interest in biopharmaceutical opportunities is slowly but surely improving in 2024, including both private investors and public-sector funders of drug development infrastructure. In mid-month